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Background:  There have been no systematic observations regarding changes in early phase insulin secretion among Korean 
prediabetes and early stage type 2 diabetes mellitus (T2DM) patients.
Methods:  We conducted 75-g oral glucose tolerance tests (OGTT) in 873 subjects with suspected abnormal glucose tolerance. 
All subjects were diagnosed as having normal glucose tolerance (NGT), prediabetes (preDM), or T2DM according to the OGTT 
results and the insulin secretory and insulin resistance indices of each subject were calculated. Additionally, we analyzed the 
changes in early phase insulin secretion according to changes in fasting (Glc0), post-prandial (Glc120) glucose and HbA1c (A1c) 
levels.
Results:  As compared to subjects with NGT, the insulin secretory indices of the preDM and T2DM subjects progressively de-
clined, and the insulin resistance indices were progressively aggravated. Early phase insulin secretion decreased rapidly accord-
ing to the increments of Glc0, Glc120 and A1c, and these changes were most prominent in the NGT stage. Compared to the con-
trol group, the early phase insulin secretion levels of the preDM or T2DM subjects were less than 50% when Glc0 was over 100 
mg/dL, Glc120 was over 145 mg/dL, and A1c was over 5.8%.
Conclusion:  This study suggests that progressive beta cell dysfunction in Koreans may be initiated and rapidly aggravated dur-
ing the period generally designated as ‘normal.’
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INTRODUCTION
Increased insulin resistance and reduced insulin secretion have 
been identified as key players in the pathogenesis of type 2 dia-
betes mellitus (T2DM) [1,2]. In particular, the reduced insulin 
secretion resulting from beta cell dysfunction is altered more 
dynamically compared with that of the insulin resistance seen 
in the development of disease to non-diabetic hyperglycemia 
and T2DM, and this is assumed to be the most direct and most 
important cause of clinical hyperglycemia [3-9].
  The origin of the substantial elevation of blood glucose in 
beta cell dysfunction indicates that significant functional chang-
es in beta cells may occur at a specific period of glucose metabo-
lism impairment, and thus, it is necessary to evaluate accurately 
both the pattern and clinical significance of this period. Howev-
er, the current diagnostic criteria for T2DM were established 
based on the risk of developing chronic microvascular compli-
cations [10-15]. Accordingly, there is no clinical relationship be-
tween the time point at which significant change in pancreatic 
function occurs and the current diagnostic criteria. Therefore, 
the current criteria regarding diabetes mellitus cannot be con-
sidered to represent a direct index of beta cell dysfunction.
Original Article
Korean Diabetes J 2010;34:157-165
doi: 10.4093/kdj.2010.34.3.157
pISSN 1976-9180 · eISSN 2093-2650158
Rhee SY, et al.
Korean Diabetes J 2010;34:157-165 www.e-kdj.org
  Currently, a relatively complex technique is required to evalu-
ate human insulin secretion. However, there have not been a 
great number of relevant studies conducted to evaluate this tech-
nique. According to several studies conducted with Caucasian 
and Hispanic subjects, reduced insulin secretion is assumed to 
begin in patients who can be categorized as having normal glu-
cose tolerance (NGT) on the basis of current diagnostic criteria 
[16-18]. This indicates that beta cell dysfunction progresses, 
causing abnormal glucose metabolism, prior to the ‘prediabe-
tes’ period of the current criteria.
  In particular, according to several recently conducted stud-
ies, increased insulin resistance is not marked, and the beta cell 
capacity is relatively lower in Asian people, including Koreans, 
compared to those of Western individuals [19-22]. It is therefore 
assumed that insulin secretory dysfunction, rather than insulin 
resistance, may play a more important role in the progression of 
T2DM. However, there have been no systematic analyses con-
ducted thus far to assess the changes in insulin secretion depend-
ing on the changes in glucose tolerance in Koreans.
  Given this background, we conducted this study to assess 
changes in early phase insulin secretion depending on the glu-
cose tolerance statuses of Koreans with non-diabetic hypergly-
cemia and those with early stage T2DM without a long disease 
history of hyperglycemia, with no history of medication that 
would affect glucose tolerance with well-preserved glucose me-
tabolism.
METHODS
Subjects
Among patients who visited the Department of Endocrinolo-
gy and Metabolism at the Kyung Hee University Hospital dur-
ing a period ranging from May 2003 to December 2006 and 
underwent 75 g oral glucose tolerance tests (OGTT), this study 
included 873 subjects who had been diagnosed with hypergly-
cemia in the previous three months and who had no history of 
medication that would affect glucose tolerance. To minimize the 
outside influences on insulin secretion and insulin resistance 
that might occur due to the duration of, medication for, or other 
interventions related to hyperglycemia, all subject recruitment 
was designed to place a limitation on the time point at which 
hyperglycemia was diagnosed and the types of medications 
prescribed. Before the study was initiated, the protocols for 
this study were approved by the Institutional Review Board of 
Kyung Hee University Hospital.
Methods
Clinical characteristics
Prior to the 75 g OGTT, patients’ past medical histories, family 
histories, and smoking histories were investigated. Basal anthro-
pometry was evaluated to determine patients’ height, weight, 
body mass index (BMI), abdominal circumference (AC) and 
resting blood pressure. Blood sampling and analyses were con-
ducted to measure total cholesterol (TC), high density lipopro-
tein cholesterol (HDL-C), low density lipoprotein cholesterol 
(LDL-C), triglycerides (TG) and glycosylated hemoglobin (A1c).
OGTT
OGTT was conducted by measuring plasma glucose (Glc0), 
insulin (Ins0), and C-peptide (Cpep0) concentration after a 
minimum eight-hour fasting period. After oral glucose load-
ing, plasma glucose concentrations were measured at 30, 60, 
90, and 120 minutes, and serum insulin (Ins30) and C-peptide 
(Cpep30) concentrations were measured 30 minutes after glu-
cose loading. On the basis of the OGTT results, all study sub-
jects were categorized into three groups: NGT, prediabetes 
(preDM) and overt T2DM. The diagnostic criteria were based 
on those established by the American Diabetes Association [14].
Biochemical analysis
Serum TC and TG levels were determined via enzymatic as-
says, and serum HDL-C was determined via a precipitation 
assay. LDL-C was determined using a homogenous assay, and 
HbA1c was measured via high-performance liquid chroma-
tography (G7; Tosoh Co., Tokyo, Japan). Plasma glucose was 
determined via the hexokinase method using a glucose ana-
lyzer (Automatic Analyzer; Hitachi, Tokyo, Japan), and plasma 
insulin and C-peptide levels were measured using an immu-
noradiometric assay (Insulin: Insulin Riabead II, C-peptide: 
Daiichi III; both SRL, Tokyo, Japan).
Calculation of insulin secretion and insulin resistance indices
Based on the OGTT results, indices for insulin secretion in-
cluding the insulinogenic index (IGI), acute C-peptide response 
(ACR) and homeostasis model assessment β (HOMAβ), as well 
as insulin resistance indices including the homeostasis model 
assessment-insulin resistance (HOMA-IR) and QUICKI were 
calculated based on formulas described below [23-26]. 
Among these, IGI and ACR were used to measure the changes 
in insulin and C-peptide concentrations depending on the chang-
es in plasma glucose concentration measured 30 minutes prior 159
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to and after oral glucose loading. Therefore, these measurements 
were utilized in the current study as an indicator for early insu-
lin secretion.
 
IGI = (Ins30 – Ins0) / (Glc30 – Glc0)
ACR = (Cpep30 – Cpep0) / (Glc30 – Glc0)
HOMAβ = (20 × Ins0) / [(Glc0 / 18) – 3.5]
HOMA-IR = (Ins0 × Glc0) / 405
QUICKI = 1 / [Ln(Ins0) + Ln(glc0 / 18)]
Ins0, fasting plasma insulin (mIU/L); Ins30, insulin 30 minutes 
after glucose intake (mIU/L); Cpep0, fasting plasma C-peptide 
(ng/mL); Cpep30, C-peptide 30 minutes after glucose intake 
(ng/mL); Glc0, fasting plasma glucose (mg/dL); Glc30, plasma 
glucose 30 minutes after glucose intake (mg/dL)
 
Data analysis
Among the NGT, preDM and T2DM groups, comparisons were 
conducted to determine the differences in clinical characteris-
tics, insulin secretions and insulin resistance indices. Adjust-
ments were made for the covariates of age, BMI and AC, and 
then another comparison was conducted.
  After these comparisons were made, all study subjects were 
divided according to 1) fasting glucose (F1: Glc0 ≤ 86 mg/dL, n 
= 72; F2: Glc0 87-95 mg/dL, n = 76; F3: Glc0 96-100 mg/dL, n = 
81; F4: Glc0 101-105 mg/dL, n = 70; F5: Glc0 106-110 mg/dL, n 
= 81; F6: Glc0 111-114 mg/dL, n = 73; F7: Glc0 115-119 mg/dL, 
n = 68; F8: Glc0 120-126 mg/dL, n = 71; F9: Glc0 127-136 mg/
dL, n = 63; F10: Glc0 137-148 mg/dL, n = 73; F11: Glc0 149-184 
mg/dL, n = 73; F12: Glc0 ≥ 185 mg/dL, n = 72), 2) post loading 
2 hour plasma glucose (P1: Glc120 ≤ 112 mg/dL, n = 76; P2: 
Glc120 113-132 mg/dL, n = 71; P3: Glc120 133-145 mg/dL, n = 
73; P4: Glc120 146-161 mg/dL, n = 72; P5: Glc120 162-180 mg/
dL, n = 74; P6: Glc120 181-200 mg/dL, n = 75; P7: Glc120 201-
226 mg/dL, n = 70; P8: Glc120 227-246 mg/dL, n = 71; P9: Glc120 
247-273 mg/dL, n = 73; P10: Glc120 274-305 mg/dL, n = 74; 
P11: Glc120 306-353 mg/dL, n = 73; P12: Glc120 ≥ 354 mg/dL, n 
= 71) and 3) glycosylated hemoglobin (H1: A1c ≤ 5.0%, n = 
67; H2: A1c 5.1-5.2%, n = 51; H3: A1c 5.3-5.4%, n = 68; H4: 
A1c 5.5-5.7%, n = 96; H5: A1c 5.8-5.9%, n = 78; H6: A1c 6.0-
6.1%, n = 59; H7: A1c 6.2-6.4%, n = 77; H8: A1c 6.5-6.8%, n = 
70; H9: A1c 6.9-7.4%, n = 62; H10: A1c 7.5-8.2%, n = 66; H11: 
A1c 8.3-10.0%, n = 68; H12: A1c ≥ 10.1%, n = 69). According 
to these parameters, each group was subdivided into 12 sub-
groups, each of similar size.
  Changes in early phase insulin secretion were evaluated 
among these subgroups. However, in comparing early phase in-
sulin secretion according to variations in glucose tolerance, the 
possibility exists that many variations could occur, depending 
on individual differences in insulin resistance. Based on previ-
ous studies, comparisons were conducted using the values cal-
culated by dividing IGI and ACR by HOMA-IR (IGI/HOMA-
IR, ACR/HOMA-IR) [16,27].
Statistical analysis
Statistical analysis and data management were conducted us-
ing the SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). In or-
der to confirm the statistical significances among subgroups, 
Student’s t-test, one-way ANOVA, and the chi-square tests were 
used. To adjust for the effects of covariates, such as age, gender, 
BMI, and AC, the ANCOVA model was utilized. In order to 
confirm the relationships among IGI/HOMA-IR, ACR/HOMA-
IR and the clinical variables associated with glucose tolerance, 
a linear regression analysis was conducted, and multiple linear 
regression analysis was performed to adjust for the effects of 
confounders.
RESULTS
Clinical characteristics
Among the 873 enrolled subjects, 102 were diagnosed with 
NGT, 307 were diagnosed with preDM and 464 were diagnosed 
with T2DM according to OGTT. Characteristics were com-
pared among the three groups. Compared with the NGT group, 
subjects diagnosed with preDM and T2DM has significantly 
higher values for the majority of the variables such as age, BMI, 
AC, systolic and diastolic BP, TC, HDL-C, TG, A1c, Ins0 and 
Glc0. These parameters evidenced a progressive tendency to 
increase as glucose tolerance was aggravated (Table 1). How-
ever, we noted no significant differences in gender or LDL-C 
among the three groups.
Comparisons of the insulin secretion and insulin resistance 
indices depending on the variations in glucose tolerance
Compared with the NGT group, indices for insulin secretion 
such as IGI, ACR and HOMAβ were significantly reduced in 
the preDM and T2DM groups. As glucose tolerance aggravat-
ed, these indices progressively decreased (Table 2). Insulin re-
sistance indices also evidenced progressive and significant vari-
ations depending on the aggravation of glucose tolerance. Com-160
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pared with that of the NGT group, the HOMA-IR was signifi-
cantly increased in the preDM and T2DM groups and the QUICKI 
was significantly reduced. After adjustment for covariates such 
as age, BMI and AC, the statistical significances did not change.
IGI/HOMA-IR and ACR/HOMA-IR
Early phase insulin secretion indices, such as IGI/HOMA-IR 
and ACR/HOMA-IR, for which the indices for insulin resis-
tance were adjusted, were also noted to change significantly 
Table 1.  Clinical characteristics of study subjects
NGT
(n = 102)
PreDM
(n = 307)
T2DM
(n = 464)
P value
Age, yr  47.7 ± 15.3  51.0 ± 12.7  53.3 ± 12.0 < 0.001
Sex, M/F, n 48/54  157/150 259/205 0.188
BMI, kg/m
2 23.8 ± 4.2 25.7 ± 4.2 25.6 ± 3.4 < 0.001
AC, cm  84.7 ± 10.3 89.4 ± 9.6 90.2 ± 8.9 < 0.001
SBP, mm Hg 125.6 ± 18.2 129.7 ± 19.0 131.2 ± 18.7 0.025
DBP, mm Hg  79.6 ± 11.1  82.7 ± 12.2  84.0 ± 12.5 0.004
T-chol, mg/dL 192.8 ± 41.6 197.2 ± 43.1 203.1 ± 38.8 0.040
TG, mg/dL 139.8 ± 92.9  163.1 ± 139.9  188.3 ± 126.8 0.002
HDL, mg/dL  48.9 ± 11.8  43.4 ± 10.7  41.5 ± 11.0 < 0.001
LDL, mg/dL 117.7 ± 32.9 118.0 ± 34.2 118.3 ± 32.8 0.991
HbA1c, %  5.3 ± 0.5  5.7 ± 0.6  7.7 ± 2.1 -
Glc0, mg/dL 88.2 ± 9.7 105.5 ± 10.8 145.8 ± 46.3 -
Ins0, uU/mL  7.2 ± 6.1  9.1 ± 7.4  9.1 ± 6.2 0.024
Data are the result of ANOVA, presented as mean ± standard deviation.
NGT, normal glucose tolerance; PreDM, prediabetes; T2DM, type 2 diabetes mellitus; BMI, body mass index; AC, abdominal circumference; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; T-chol, total cholesterol; TG, triglycerides; HDL, high density lipoprotein; LDL, low 
density lipoprotein; Glc0, fasting plasma glucose; Ins0, fasting plasma insulin.
Table 2.  Comparison of insulin secretion and insulin resistance parameters according to glucose tolerance
NGT
(n = 102)
PreDM
(n = 307)
T2DM
(n = 464)
P value
Total
(n = 873)
Before adjustment
IGI 1.23 ± 1.23 0.85 ± 0.84 0.26 ± 0.35 < 0.001 0.58 ± 0.79
ACR 0.09 ± 0.09 0.06 ± 0.07 0.02 ± 0.04 < 0.001 0.04 ± 0.06
HOMAβ 110.2 ± 233.3 83.9 ± 72.1 49.4 ± 59.0 < 0.001 68.6 ± 102.0
HOMA-IR 1.57 ± 1.34 2.40 ± 2.01 3.21 ± 2.37 < 0.001 2.73 ± 2.22
QUICKI 0.76 ± 0.30 0.63 ± 0.13 0.59 ± 0.13 < 0.001 0.62 ± 0.17
After adjustment for age, BMI, and abdominal circumference
IGI 1.25 ± 0.07 0.85 ± 0.04 0.259 ± 0.033 < 0.001 -
ACR 0.09 ± 0.01 0.06 ± 0.00 0.02 ± 0.00 < 0.001 -
HOMAβ 120.2 ± 9.9 82.1 ± 5.6 48.6 ± 4.6 < 0.001 -
HOMA-IR 1.90 ± 0.20 2.33 ± 0.11 3.22 ± 0.09 < 0.001 -
QUICKI 0.73 ± 0.01 0.63 ± 0.01 0.59 ± 0.01 < 0.001 -
Data are the result of ANOVA, presented as mean ± standard deviation, and ANCOVA, presented as mean ± standard error.
NGT, normal glucose tolerance; PreDM, prediabetes; T2DM, type 2 diabetes mellitus; IGI, insulinogenic index; ACR, acute C-peptide re-
sponse; HOMA-IR, homeostasis model assessment–insulin resistance; BMI, body mass index.161
Change of early phase insulin secretion in Korean
Korean Diabetes J 2010;34:157-165 www.e-kdj.org
depending on glucose tolerance status. After linear regression 
analysis, the log-transformed values of IGI/HOMA-IR and 
ACR/HOMA-IR had higher correlation coefficients with Glc0, 
Glc120, and HbA1c. Following adjustment for various con-
founders via multivariate analysis, no changes in the statistical 
significances were noted (Table 3).
The changes in early phase insulin secretion depending on 
Glc0
Subjects were divided into 12 subgroups according to Glc0, by 
which the changes in IGI/HOMA-IR and ACR/HOMA-IR 
depending on Glc0 were assessed. As a result, according to the 
increased value of Glc0, IGI/HOMA-IR and ACR/HOMA-IR 
displayed a tendency to gradually decrease (Fig. 1).
  Comparisons were made based on the F1 group and dem-
onstrated that the decreased IGI/HOMA-IR values were sig-
nificantly different from those of subgroup F3. A comparison 
was also conducted based on the F2 group, and a statistically 
significant difference from subgroup F4 was noted (Fig. 1A). 
On the other hand, in the case of ACR/HOMA-IR, a signifi-
cant difference from subgroup F4 was noted in both the F1 
and F2 groups (Fig. 1B). In the F4 subgroup, the mean value of 
IGI/HOMA-IR was 29.4% for F1 and 61.1% for F2, and the 
mean value of ACR/HOMA-IR was 36.3% and 57.9%, respec-
tively. These results show that early phase insulin secretion was 
reduced by approximately 4% when Glc0 was increased by 1 
mg/dL in subgroups F1 to F4.
Fig. 1.  Relationship between fasting plasma glucose and early phase insulin secretion. Data represents the means and 95% con-
fidence intervals. IGI, insulinogenic index; HOMA-IR, homeostasis model assessment–insulin resistance; ACR, acute C-peptide 
response. 
aRefers to P < 0.05 vs. F1 (FPG ≤ 86 mg/dL), 
bP < 0.01 vs. F1, 
cP < 0.05 vs. F2 (FPG 87-95 mg/dL), 
dP < 0.01 vs. F2.
I
G
I
 
/
 
H
O
M
A
-
I
R
2.0
1.5
1.0
0.5
0.0
≤ 86  87  96  101  106  111  115  120  127  137  149  ≥ 185
  -95  -100  -105  -110  -114  -119  -126  -136  -148  -184
FPG
c
b d
b 
d
b  d
b 
d
b  d
b 
d
b  d
b 
c
a 
 
a 
A
C
R
 
/
 
H
O
M
A
-
I
R
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00
≤ 86  87  96  101  106  111  115  120  127  137  149  ≥ 185
  -95  -100  -105  -110  -114  -119  -126  -136  -148  -184
FPG
c
a
d
a 
d
a
d
a d
b  d
b 
d
b 
d
b 
d
b 
A B
Table 3.  Relationships among early phase insulin secretion indices adjusted by insulin resistance (IGI/HOMA-IR and ACR/
HOMA-IR) and the fasting plasma glucose, the 2-hr plasma glucose, and the HbA1c
Correlation
Univariate Multivariate*
r P value r P value
Ln_IGI/HOMA-IR Ln_FPG -0.697 <  0.001 -0.701 < 0.001
Ln_PPG -0.766 < 0.001 -0.776 < 0.001
Ln_HbA1c -0.725 < 0.001 -0.724 < 0.001
Ln_ACR/HOMA-IR Ln_FPG -0.651 < 0.001 -0.653 < 0.001
Ln_PPG -0.732 < 0.001 -0.738 < 0.001
Ln_HbA1c -0.646 < 0.001 -0.641 < 0.001
IGI, insulinogenic index; HOMA-IR, homeostasis model assessment–insulin resistance; ACR, acute C-peptide response; BMI, body mass in-
dex.
*Adjusted for age, gender, BMI, abdominal circumference, smoking, and personal medical history.162
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The changes in early phase insulin secretion depending on 
Glc120 
The subjects were divided into 12 subgroups depending on 
Glc120, by which the changes in IGI/HOMA-IR and ACR/HO-
MA-IR were evaluated depending on the increased value of 
Glc120. As a result, IGI/HOMA-IR and ACR/HOMA-IR evi-
denced a gradual tendency to decrease (Fig. 2).
  As compared with the P1 group, the reduced IGI/HOMA-
IR values were statistically significantly different from those of 
subgroup P3. A comparison was also conducted based on the 
P2 group, and this demonstrated a statistically significant dif-
ference from that of the P4 subgroup (Fig. 2A). Based on the 
P1 group with regard to ACR/HOMA-IR, the decreased ACR/
HOMA-IR value reached statistical significance from subgroup 
P3. Based on subgroup P2, ACR/HOMA-IR was decreased to a 
statistically significant from subgroup P4 (Fig. 2B). In subgroup 
P4, the mean value of IGI/HOMA-IR was 33.2% for P1 and 
53.6% for P2, the mean value of ACR/HOMA-IR value was 
27.5% and 44.8%, respectively. These results show that early 
phase insulin secretion was reduced by approximately 1.5% 
when Glc120 was decreased by 1 mg/dL in subgroups P1 to P4.
The changes in early phase insulin secretion depending on A1c
The subjects were divided into 12 subgroups depending on A1c, 
Fig. 2.  Relationship between postprandial plasma glucose and early phase insulin secretion. Data represents means and 95% con-
fidence intervals. IGI, insulinogenic index; HOMA-IR, homeostasis model assessment–insulin resistance; ACR, acute C-peptide 
response. 
aRefers to P < 0.05 vs. P1 (PP2 < 112 mg/dL), 
bP < 0.01 vs. P1, 
cP < 0.05 vs. P2 (PP2  113-132 mg/dL), 
dP < 0.01 vs. P2.
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Fig. 3.  Relationship between postprandial plasma glucose and early phase insulin secretion. Data represents means and 95% con-
fidence intervals. IGI, insulinogenic index; HOMA-IR, homeostasis model assessment–insulin resistance; ACR, acute C-peptide 
response. 
aRefers to P < 0.05 vs. H1 (HbA1c < 5.0%), 
bP < 0.01 vs. H1, 
cP < 0.05 vs. H2 (HbA1c 5.1-5.2%), 
dP < 0.01 vs. H2.
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by which the changes in IGI/HOMA-IR and ACR/HOMA-IR 
were evaluated depending on the increased A1c value. As a re-
sult, according to the increased A1c values, IGI/HOMA-IR and 
ACR/HOMA-IR tended to gradually decrease (Fig. 3).
  Based on subgroup H1, the decreased IGI/HOMA-IR value 
reached statistical significance with respect to subgroup H4. 
Based on the H2 subgroup, a statistically significant difference 
was noted with respect to subgroup H4 (Fig. 3A). Based on the 
H1 group with regard to ACR/HOMA-IR, the decreased ACR/
HOMA-IR value reached statistical significance from subgroup 
H5. Based on subgroup H2, ACR/HOMA-IR was decreased to 
a statistically significant from subgroup H4 (Fig. 3B). In sub-
group H4, mean IGI/HOMA-IR was 39.4% for H1 and 51.4% 
for H2, and mean ACR/HOMA-IR values were 44.0% and 
53.6%, respectively. These results show that early phase insulin 
secretion decreased by approximately 10% when A1c was in-
creased by 0.1% in subgroups H1 to H4.
DISCUSSION
In this study, we assessed the changes in early phase insulin se-
cretion depending on variations in glucose tolerance based on 
the results of OGTT, performed in a relatively large Korean 
sample. In particular, subjects without a medication history that 
would affect glucose tolerance and in whom the duration of hy-
perglycemia was within a selected duration. Attempts were 
made to minimize the confounders and to reflect the results that 
were closest to the actual effects of the diseases. Additionally, to 
effectively adjust for the effects of insulin resistance on individ-
ual changes in insulin secretion, the changes in beta cell dys-
function could be accurately confirmed with the use of IGI/
HOMA-IR and ACR/HOMA-IR [16,27].
  As a result, in subjects with a 100 mg/dL Glc0, 145 mg/dL 
Glc120 and > 5.8% A1c, early phase insulin secretion was re-
duced to < 50% of that of the control group. Compared with 
the changes measured thereafter, the changes in insulin secre-
tion during this period were the most abrupt. Based on current 
diagnostic criteria, people who were identified as having NGT 
exhibited a dramatic deterioration of beta cell function. Based 
on the assumption that substantial elevation of blood glucose 
concentration is dependent on beta cell dysfunction, these re-
sults show that a preventive approach to beta cell dysfunction 
might be mandatory prior to the period we currently refer to as 
‘prediabetes’.
  The current diagnostic criteria for T2DM are based on the 
time point at which the risks of developing microvascular com-
plications increase in association with fasting plasma glucose, 
based on the results of a study which included Pima Indians, 
Egyptians and the National Health and Nutrition Examination 
Survey III [10-14]. Therefore, strictly speaking, these criteria 
may prove useful in predicting the occurrence of complica-
tions. However, they do not directly reflect beta cell dysfunc-
tion, a rudimentary pathophysiological mechanism of T2DM. 
The management aim of T2DM is to prevent diabetes-related 
chronic complications. Accordingly, a sufficient degree of va-
lidity with the current criteria appears to exist. However, un-
der the definition that ‘prediabetes’ is a period during which the 
risks of developing T2DM are increased and thus preventive 
efforts are accordingly necessary, the results of the current 
study illustrate that the current ‘prediabetes’ criteria should be 
modified. On the other hand, according to the International 
Expert Committee, the use of A1c for the diagnosis of T2DM, 
has been recommended. In association with this, and in con-
sideration of the results of the current study, the A1c reference 
value can be proposed as an assessment criterion for subjects 
at high risk for T2DM [28].
  Our study had several limitations. The study was conducted 
following the recruitment of a relatively large number of sub-
jects, but was conducted at only one center. Thus, the exten-
sion of the results of our subject population to all Korean peo-
ple in association with the pathophysiology of T2DM is some-
what problematic. Also, in this study, the subjects were cross-
sectionally analyzed; accordingly, no prospective analysis could 
be conducted to assess individual changes depending on dis-
ease progression. The indices used in this study, IGI, ACR, 
HOMA-IR, IGI/HOMA-IR and ACR/HOMA-IR are not gold 
standards for the evaluation of early phase insulin secretion 
and insulin resistance. Errors associated with these uses, then, 
cannot be eliminated. Additionally, the measurements for in-
sulin secretion used in the current study were based on oral 
glucose loading; therefore, the possibility remains that errors 
may have been generated depending on the effect of incretin.
  Despite these limitations, this study is significant in that it 
provides baseline information by evaluating the effects of chang-
es in decreased early phase insulin secretion on the pathogene-
sis of T2DM in Koreans. Furthermore, from the perspective of 
beta cell dysfunction, a new consideration of a high-risk group 
for T2DM is necessary. It has been well-established that a vari-
ety of studies are necessary to demonstrate the validity of this 
definition. Furthermore, it has been determined that the ef-164
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fects of incretin on abnormality in the early stage in associa-
tion with glucose metabolism are not relatively greater and 
may have no serious effects on the results of the current study 
[29]. In Korea, large-scale, prospective, multi-center cohort 
studies such as the Korean National Diabetes Project (KNDP) 
are currently underway. It is, therefore, expected that the 
pathophysiology of early-phase diabetes in the Korean popula-
tion will be a subject for a great deal of future discussion.
ACKNOWLEDGEMENT
This study was supported by a grant from the Korea Health 21 
R&D Project, Ministry of Health & Welfare, Republic of Korea 
(Grant No. A050463). The authors appreciate the efforts of Ms. 
Young Ji Yoon in the preparation of the manuscript.
  
REFERENCES
 
1. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med 
Clin North Am 2004;88:787-835.
2. UKPDS study group. U.K. Prospective diabetes study 16. 
Overview of 6 years’ therapy of type ii diabetes: a progressive 
disease. U.K. Prospective diabetes study group. Diabetes 
1995;44:1249-58.
3. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural his-
tory of insulin secretory dysfunction and insulin resistance in 
the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 
104:787-94.
4. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, 
Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C. 
Impaired glucose tolerance as a disorder of insulin action: lon-
gitudinal and cross-sectional studies in pima Indians. N Engl J 
Med 1988;318:1217-25.
5. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Ben-
nett PH. Sequential changes in serum insulin concentration 
during development of non-insulin-dependent diabetes. Lan-
cet 1989;1:1356-9.
6. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: 
phases leading to type 2 (non-insulin-dependent) diabetes 
mellitus in the rhesus monkey. Diabetologia 1986;29:713-9.
7. Reaven GM, Hollenbeck CB, Chen YD. Relationship between 
glucose tolerance, insulin secretion, and insulin action in non-
obese individuals with varying degrees of glucose tolerance. 
Diabetologia 1989;32:52-5.
8. Kahn SE. Clinical review 135: the importance of beta-cell fail-
ure in the development and progression of type 2 diabetes. J 
Clin Endocrinol Metab 2001;86:4047-58.
9. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-
cell dysfunction and insulin resistance in type 2 diabetes. Eur J 
Clin Invest 2002;32 Suppl 3:35-45.
10. American Diabetes Association. Report of the expert commit-
tee on the diagnosis and classification of diabetes mellitus. Di-
abetes Care 1997;20:1183-97.
11. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, 
Bennett PH, Knowler WC. Plasma glucose and prediction of 
microvascular disease and mortality: evaluation of 1997 Amer-
ican Diabetes Association and 1999 World Health Organiza-
tion criteria for diagnosis of diabetes. Diabetes Care 
2000;23:1113-8.
12. DECODE study group. Glucose tolerance and cardiovascular 
mortality: comparison of fasting and 2-hour diagnostic criteria. 
Arch Intern Med 2001;161:397-405.
13. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. 
Postchallenge hyperglycemia and mortality in a national sam-
ple of U.S. adults. Diabetes Care 2001;24:1397-402.
14. American Diabetes Association. Diagnosis and classification 
of diabetes mellitus. Diabetes Care 2004;27 Suppl 1:S5-10.
15. Forouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, 
Qiao Q, Spijkerman A, Stolk R, Tabac A, Wareham NJ. The 
threshold for diagnosing impaired fasting glucose: a position 
statement by the European Diabetes Epidemiology Group. Di-
abetologia 2006;49:822-7.
16. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFron-
zo RA. Beta-cell dysfunction and glucose intolerance: results 
from the San Antonio metabolism (SAM) study. Diabetologia 
2004;47:31-9.
17. Godsland IF, Jeffs JA, Johnston DG. Loss of beta cell function 
as fasting glucose increases in the non-diabetic range. Diabe-
tologia 2004;47:1157-66.
18. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat 
T, Kochba I, Rudich A. Normal fasting plasma glucose levels 
and type 2 diabetes in young men. N Engl J Med 2005;353: 
1454-62.
19. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, 
Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim HS, Lee IK, 
Bonner-Weir S. Selective beta-cell loss and alpha-cell expan-
sion in patients with type 2 diabetes mellitus in Korea. J Clin 
Endocrinol Metab 2003;88:2300-8.
20. Rhee SY, Chon S, Oh S, Kim SW, Kim JW, Kim YS, Woo JT. In-
sulin secretion and insulin resistance in newly diagnosed, drug 165
Change of early phase insulin secretion in Korean
Korean Diabetes J 2010;34:157-165 www.e-kdj.org
naive prediabetes and type 2 diabetes patients with/without 
metabolic syndrome. Diabetes Res Clin Pract 2007;76:397-403.
21. Rhee SY, Kwon MK, Park BJ, Chon S, Jeong IK, Oh S, Ahn KJ, 
Chung HY, Kim SW, Kim JW, Kim YS, Woo JT. Differences in 
insulin sensitivity and secretory capacity based on OGTT in 
subjects with impaired glucose regulation. Korean J Intern 
Med 2007;22:270-4.
22. Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunc-
tion and insulin resistance in the pathogenesis of Korean type 
2 diabetes mellitus. Metabolism 2001;50:590-3.
23. Kosaka K, Kuzuya T, Hagura R, Yoshinaga H. Insulin response 
to oral glucose load is consistently decreased in established non-
insulin-dependent diabetes mellitus: the usefulness of decreased 
early insulin response as a predictor of non-insulin-dependent 
diabetes mellitus. Diabet Med 1996;13(9 Suppl 6):S109-19.
24. Kosaka K, Hagura R, Kuzuya T, Kuzuya N. Insulin secretory re-
sponse of diabetics during the period of improvement of glu-
cose tolerance to normal range. Diabetologia 1974;10:775-82.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher 
DF, Turner RC. Homeostasis model assessment: insulin resis-
tance and beta-cell function from fasting plasma glucose and 
insulin concentrations in man. Diabetologia 1985;28:412-9.
26. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sulli-
van G, Quon MJ. Quantitative insulin sensitivity check index: 
a simple, accurate method for assessing insulin sensitivity in 
humans. J Clin Endocrinol Metab 2000;85:2402-10.
27. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. Beta-
cell function is a major contributor to oral glucose tolerance in 
high-risk relatives of four ethnic groups in the U.S. Diabetes 
2002;51:2170-8.
28. International Expert Committee. International Expert Com-
mittee report on the role of the A1C assay in the diagnosis of 
diabetes. Diabetes Care 2009;32:1327-34.
29. Muscelli E, Mari A, Natali A, Astiarraga BD, Camastra S, Fr-
ascerra S, Holst JJ, Ferrannini E. Impact of incretin hormones 
on beta-cell function in subjects with normal or impaired glu-
cose tolerance. Am J Physiol Endocrinol Metab 2006;291: 
E1144-50.